» Articles » PMID: 30684301

Metastatic Immune Infiltrates Correlate with Those of the Primary Tumour in Canine Osteosarcoma

Overview
Journal Vet Comp Oncol
Date 2019 Jan 27
PMID 30684301
Citations 10
Authors
Affiliations
Soon will be listed here.
Abstract

Our lack of understanding of the immune microenvironment in canine osteosarcoma (cOSA) has limited the identification of potential immunotherapeutic targets. In particular, our ability to utilize readily available tissue from a dog's primary tumour to predict the type and extent of immune response in their pulmonary metastatic lesions is unknown. We, therefore, collected 21 matched pairs of primary tumours and pulmonary metastatic lesions from dogs with OSA and performed immunohistochemistry to quantify T-lymphocyte (CD3), FOXP3+ cell, B-lymphocyte (Pax-5), and CD204+ macrophage infiltration. We found that T-lymphocytes and FOXP3+ infiltrates in primary tumours positively correlated with that of metastatic lesions (ρ = 0.512, P = 0.038 and ρ = 0.698, P = 0.007, respectively), while a strong trend existed for CD204+ infiltrates (ρ = 0.404, P = 0.087). We also observed T- and B-lymphocytes, and CD204+ macrophages to be significantly higher in a dog's pulmonary metastasis compared to their primary tumour (P = 0.018, P = 0.018, P = 0.016, respectively), while FOXP3+ cells were only significantly higher in metastases when all primary tumour and metastasis lesions were compared without pairing (P = 0.036). Together, these findings suggest that the metastatic immune microenvironment may be influenced by that of the primary cOSA, and that primary tumour immune biomarkers could potentially be applied to predict immunotherapeutic responses in gross metastatic disease. We, therefore, provide a rationale for the treatment of cOSA pulmonary metastases with immunotherapeutics that enhance the anti-tumour activity of these immune cells, particularly in dogs with moderate to high immune cell infiltration in their primary tumours.

Citing Articles

Characterization of canine tumor-infiltrating leukocyte transcriptomic signatures reveals conserved expression patterns with human osteosarcoma.

Ammons D, Harris R, Chow L, Dow S Cancer Immunol Immunother. 2025; 74(3):105.

PMID: 39932553 PMC: 11813853. DOI: 10.1007/s00262-025-03950-3.


Tumor-associated macrophages in canine visceral hemangiosarcoma.

Kerboeuf M, Haugeberg D, Olsen T, Sorling L, Koppang E, Moe L Vet Pathol. 2023; 61(1):32-45.

PMID: 37341055 PMC: 10687809. DOI: 10.1177/03009858231179947.


Tumor-associated macrophages: Prognostic and therapeutic targets for cancer in humans and dogs.

Brady R, Thamm D Front Immunol. 2023; 14:1176807.

PMID: 37090720 PMC: 10113558. DOI: 10.3389/fimmu.2023.1176807.


Comparative Evaluation of Tumor-Infiltrating Lymphocytes in Companion Animals: Immuno-Oncology as a Relevant Translational Model for Cancer Therapy.

Pinard C, Lagree A, Lu F, Klein J, Oblak M, Salgado R Cancers (Basel). 2022; 14(20).

PMID: 36291791 PMC: 9599753. DOI: 10.3390/cancers14205008.


Exploring the association of intratumoral immune cell infiltrates with histopathologic grade in canine mast cell tumors.

Costa V, Soileau A, Liu C, Moeller C, Carossino M, Langohr I Res Vet Sci. 2022; 147:83-91.

PMID: 35490489 PMC: 11293894. DOI: 10.1016/j.rvsc.2022.04.005.


References
1.
Kurzman I, Shi F, Vail D, MacEwen E . In vitro and in vivo enhancement of canine pulmonary alveolar macrophage cytotoxic activity against canine osteosarcoma cells. Cancer Biother Radiopharm. 2000; 14(2):121-8. DOI: 10.1089/cbr.1999.14.121. View

2.
Coronella J, Spier C, Welch M, Trevor K, Stopeck A, Villar H . Antigen-driven oligoclonal expansion of tumor-infiltrating B cells in infiltrating ductal carcinoma of the breast. J Immunol. 2002; 169(4):1829-36. DOI: 10.4049/jimmunol.169.4.1829. View

3.
Nzula S, Going J, Stott D . Antigen-driven clonal proliferation, somatic hypermutation, and selection of B lymphocytes infiltrating human ductal breast carcinomas. Cancer Res. 2003; 63(12):3275-80. View

4.
Boston S, Ehrhart N, Dernell W, Lafferty M, Withrow S . Evaluation of survival time in dogs with stage III osteosarcoma that undergo treatment: 90 cases (1985-2004). J Am Vet Med Assoc. 2006; 228(12):1905-8. DOI: 10.2460/javma.228.12.1905. View

5.
Lang D, Powell S, Plummer R, Young K, Ruggeri B . PAX genes: roles in development, pathophysiology, and cancer. Biochem Pharmacol. 2006; 73(1):1-14. DOI: 10.1016/j.bcp.2006.06.024. View